REGN

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.